---
schema_version: "secwatch.filing_event.v1"
accession: "0000899923-24-000025"
form_type: "8-K"
ticker: "MYGN"
cik: "0000899923"
company_name: "MYRIAD GENETICS INC"
filed_at: "2024-05-07T23:59:59+00:00"
generated_at: "2026-06-02T21:31:21.904941+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Myriad Genetics Q1 revenue $202M (+12% YoY), positive adjusted EBITDA $4M, reiterates FY guidance

## Summary
- Q1 revenue $202.2M (+12% YoY); GAAP net loss narrowed to $26M from $55M.
- Adjusted EPS -$0.01 vs -$0.21 YoY; positive adjusted EBITDA $4M vs -$19M.
- Revenue growth driven by Prenatal (+22%), Pharmacogenomics (+21%), Hereditary Cancer (+16%).
- Announced sale of EndoPredict to Eurobio Scientific; retains U.S. license.
- Reiterates FY2024 guidance: revenue $820-840M, adjusted EBITDA $20-30M, adjusted EPS $0.00-$0.05.

## SEC filing metadata
- accession: 0000899923-24-000025
- form_type: 8-K
- ticker: MYGN
- cik: 0000899923
- company_name: MYRIAD GENETICS INC
- filed_at: 2024-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/899923/000089992324000025/0000899923-24-000025-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/899923/000089992324000025/mygn-20240507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000899923-24-000025
- JSON: https://secwatch.observer/filing/0000899923-24-000025.json
- Plain text: https://secwatch.observer/filing/0000899923-24-000025.txt

## Key facts
- Earnings Releases
  MYRIAD GENETICS INC reported first quarter ended March 31, 2024 results: revenue $202.2 million, net income $26 million, EPS $(0.29). Guidance reaffirmed.
  - Period: first quarter ended March 31, 2024
  - Revenue: $202.2 million
  - Net income: $26 million
  - EPS: $(0.29)
  - Guidance: reaffirmed
  - Result: reported results
  source text: Results; Achieves 12% Revenue Growth Year-Over-Year; Significantly Improved Year-Over-Year Net Loss and Generated Positive Adjusted EBITDA Highlights: • First quarter revenue of $202 million grew 12% year-over-year, driven by Prenatal (22%), Pharmacogenomics (21%), and Hereditary Cancer (16%). First quarter average revenue per test improved by 2% over the prior year
  evidence_url: https://www.sec.gov/Archives/edgar/data/899923/000089992324000025/0000899923-24-000025-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.